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Genetic mapping of modifier loci affecting malignant hyperten- Malignant hypertension (MH) is a severe form of hyper-
sion in TGRmRen2 rats. tension with end organ damage occurring in 1 to 2% of the
Background. Genetic background has a major influence on hypertensive population [1–3]. The increasing frequency
the manifestation of multifactorial diseases such as hyperten- of diagnosis of mild-to-moderate hypertension and the
sion in which severe complications may be caused through an
widespread use of antihypertensive medication have gen-interaction with additional factors, which may be genetically
erally resulted in a decreased incidence of MH and an im-determined. We have previously described a genetic model of
provement in the prognosis of affected patients [4]; how-malignant hypertension (MH) in rats carrying the mouse Ren2
gene (TGRmRen2-27), in which the phenotype is dependent ever, in some populations, MH has failed to decline [5].
on the genetic background. Clinical markers of transformation to the accelerated
Methods. Using a single homozygous TGRmRen2-27 male as phase include a rising blood pressure, a presumed pres-
transgene donor, we produced two F1 populations with (a) 100% sure diuresis, renal failure, and the development of grade
penetrance of MH in progeny heterozygous for the Fischer F344 III or IV retinopathy [3]. The severe increase in bloodgenetic background and (b) 58.5% penetrance in progeny het-
pressure may cause endothelial damage and proliferationerozygous for the Lewis genetic background. To identify the
of myointimal cells, resulting in pathological changes inmodifier loci affecting the phenotype, a cohort of 252 males was
the vasculature, including “onion skinning” with endo-produced by breeding the same single male with Fischer-Lewis
F1 females. The progeny were phenotyped for clinical and patho- thelial swelling and fibrinoid necrosis [6, 7]. As a conse-
logical features of MH. quence, renal ischemia triggers the activation of the renin-
Results. Genome-wide screening and quantitative trait loci angiotensin system (RAS), causing a further elevation
(QTL) analysis identified two loci, on chromosome 10 (LOD in arterial blood pressure. Moreover, enhanced shear
4.4) and on chromosome 17 (LOD 3.9) close to the Ace and
stress in the severely narrowed microcirculation may fur-At1 genes, respectively, which contribute to the lethal MH phe-
ther endothelial injury and platelet aggregation, whichnotype. Their influence on mortality was consistent with a multi-
sustain the microangiopathic process.plicative effect of the two loci. In addition, we found higher
plasma angiotensin-converting enzyme activity in progeny re- The predisposing and initiating factors of malignant-
ceiving the Fischer allele than in progeny receiving the Lewis phase hypertension are not well understood. The level of
allele (123.5 6 9.5 vs. 91.8 6 4.9 U/liter, P , 0.01), suggesting hypertension alone may not be the sole factor determin-
the association of angiotensin-converting enzyme and MH. ing the development of this complication because there is
Conclusions. Our study demonstrates the application of a a considerable overlap in actual blood pressures betweentransgene as a “major gene” to facilitate the identification of
MH patients and benign hypertensives [8]. The racialmodifier loci, which can affect the phenotype of MH, and
difference in the incidence of malignant nephrosclerosisreveals Ace and At1 as candidate genes involved in the manifes-
and hypertension-associated end-stage renal failure intation of the MH phenotype.
black compared with white hypertensive patients even
after the adjustment for socioeconomic variables [9, 10]
suggests the primary role of genetic predisposition. It isKey words: gene mapping, hypertension, cardiovascular, transgenic rat,
renin-angiotensin system. conceivable that one or more genetic polymorphisms in
the individual may interact in response to high blood pres-Received for publication November 13, 1998
sure and may determine the severity of vascular injury.and in revised form March 18, 1999
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actions causing phenotypic variation in the human popu- Genetic markers and fluorescent-dUTP genotyping
lation. We have recently described a rat model of MH Seventy-two animals, 36 survivors ($120 days of age)
that results from the expression of a mouse Ren2 renin and 36 with MH at an early age, were studied using 125
transgene [11]. The penetrance of the MH phenotype was informative markers that covered more than 90% of the
found to be highly dependent on the genetic background, rat genome at less than 20 cM intervals. Candidate loci
and the pathophysiological changes in MH rats were very that showed a LOD score of more than 1.5 were then
similar to those observed in the human disease [11, 12]. To analyzed further by genotyping all 252 animals. The poly-
identify modifier genes of MH, we used the transgene to morphic markers between Lewis and Fischer strains were
stimulate the phenotype in a diverse genetic background chosen with reference to published information (genetic
and found the linkage of the MH phenotype to two loci, map [14], http://www.genome.wi.mit.edu) and allele size
information from Genosys Biotechnologies (Cambridge,containing the candidate genes Ace and At1, which may
UK). Polymerase chain reaction (PCR) primers for thecontribute to the severity of the MH phenotype.
markers were obtained from Research Genetics (Hunts-
ville, AL, USA) and Genosys Biotechnologies (Cam-
METHODS bridge, UK). PCR reactions were performed in flexible
Animal crosses and phenotype assessments Thermo-Fast 96-well plates (Advanced Biotechnologies,
Surrey, UK) in a total volume of 10 ml containing 150Fischer (Fischer F344), Lewis, and Fischer-Lewis F1
ng of template DNA, 330 nm of each primer, 200 mmfemale rats were obtained from Harlan-Olac (Oxford,
dNTPs, 1 3 buffer (Promega, Southampton, UK), 0.5 UUK). The transgenic rat TGRmRen2-27 is a hypertensive
of Taq polymerase (Promega), and 1.5 mm MgCl2. Therat strain that expresses the mouse Ren2 renin gene and
ratio of F-dUTP to dTTP was 1:400 for R110 and R6Gthat is maintained on a Sprague-Dawley (SD) back-
and 1:200 for TAMRA (Applied Biosystems, Warring-ground [13]. We minimized the potential for variation
ton, UK). Reactions were overlaid with 40 ml of lightin penetrance because of different SD alleles by using a
mineral oil and amplified on an Omnigene thermocyclersingle male homozygous TGRmRen2-27 rat (known to
(Hybaid, Middlesex, UK) using the following protocol:be 90% homozygosity based on our analysis of microsa-
initial denaturation at 948C for five minutes, followed bytellite markers) to sire all of the offspring studied. On
30 cycles at 948C for one minute, 558C for one minute,the basis of our previous data [12], male progeny were
728C for 1.5 minutes, and final extension at 728C for tenchosen for this investigation.
minutes. The PCR products from five microsatelliteAll animals used in this study were bred at the Center
markers with nonoverlapping allele size and that werefor Genome Research (University of Edinburgh, Edin-
labeled with different fluorescent dyes were pooled andburgh, United Kingdom). Rats were housed with free
phenol-chloroform extracted. Three and one-half micro-
access to food and water throughout the experimental
liters of the loading cocktail, containing 1:5 (vol/vol) of
period and were fed standard commercial rat chow sup- size standard (GENESCAN 500-ROX), formamide/blue
plied by Special Diet Services (Witham, Essex, UK). dextran and ethylenediaminetetraacetic acid (EDTA) as
Regular 12-hour diurnal cycles were maintained. The in the manufacturer’s protocol, was added to 1.5 ml of the
breeding, maintenance, and study of animals were per- pooled samples. The samples were then heated at 958C
formed according to home office regulations. Tail cuff for three minutes, and 2 ml of the sample were loaded
plethysmography was performed under light halothane onto an individual gel lane. Electrophoresis was carried
anesthesia at six and eight weeks of age prior to the devel- out using 4% acrylamide/6 m urea, 36 cm (36 cm Well-
opment of MH, as previously described [12]. The rats that to-Read) gels, using a model 377 Sequencer (Applied
developed symptoms of MH were killed by either CO2 Biosystems). Analysis was performed using the Gene-
inhalation or cervical dislocation. Blood was collected in Scane 2.0.0 software and Genotypere (version 1.1; Ap-
a heparinized tube and centrifuged at 48C for six minutes. plied Biosystems) as described in the manufacturer’s man-
The plasma was kept at 2708C for determination of angio- ual. Data were exported and stored in Excel (version 4.0).
tensin-converting enzyme (ACE) activity. The kidneys
Measurement of angiotensin-convertingwere removed and fixed in 10% formal saline prior to his-
enzyme activitytopathological study using hematoxylin and eosin (H&E),
periodic acid-Schiff, and Martius Scarlet Blue (MSB)- Plasma ACE activity was measured kinetically on a
stained sections as previously reported [12]. The sections Cobas Mira Plus analyzer using the substrate furylacryl-
were examined for malignant vascular injury, defined by ylphenylalanylglycylglycine (FAPGG; Sigma, Dorset,
fibrinoid necrosis and myointimal proliferation of arter- UK) and the method of Maguire and Price [15]. FAPGG
ies and arterioles, by two pathologists (S.F. and K.K.) is hydrolyzed by ACE to furylacrylylphenylalanine and
glycylglycine, which results in a decrease in absorbancewithout prior knowledge of survival and genetic data.
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Fig. 1. Distribution of age at time of death of the progeny of
TGRmRen2-27 and F1 (Fischer-Lewis). Out of 252 male progeny, 200
had died by 120 days in total over a range of 49 to 119 days. The median
age at time of death was 60 days, with a mean of 63.3 days 6 sd 12.2
days.
Fig. 3. Tail cuff systolic blood pressure (SBP) measurement of the
progeny of TGRmRen2-27 and F1 (Fischer-Lewis) prior to the develop-
ment of malignant hypertension (MH). Data are expressed as mean 6
sem. Symbols are: (d) MH; (h) survivors.
Statistical analysis
The genetic map and orders of the markers were ob-
tained for each chromosome using Cri-map [16]. Poten-
tial genotyping errors were identified on the basis of
inconsistency with Mendelian inheritance and unlikely
double recombination events. The genotypes involved
were repeated, and where necessary, the data were re-
analyzed. The linkage and quantitative trait loci (QTL)
analyses were performed by considering phenotypes as
“survival” (no clinical symptoms of MH by 120 days of
age) or the “age of death (AoD),” respectively. Interval
mapping analysis for QTLs was performed using least
squares methods, which have been found to be powerful
and robust for analysis of both normal and binary data
[17, 18]. LOD values from these analyses were calculated
from transformation of the F statistic [17]. Dam and
parity of litter were included as fixed effects in the analy-
ses. LOD values were compared with a genome-wide sig-
nificance threshold for a backcross of 3.3 [19]. We used
odds ratio (OR) and its confidence interval (CI) to esti-
mate the strength of association [20]. The comparison of
mean between groups was made using unpaired t-test andFig. 2. Histopathology of kidney. The kidneys of animals exhibiting
clinical symptoms of malignant hypertension show myointimal prolifer- two-tailed P values. Data are expressed as mean 6 sem.
ation and fibrinoid necrosis of arteries and arterioles. (A) Hematoxylin
and eosin. (B) Martius Scarlet Blue.
RESULTS
The malignant hypertensive phenotype
in genetic crossesat 340 nm, from which the ACE activity can be calcu-
lated. The samples were studied in duplicate, and the We bred a single homozygote male transgenic rat
TGRmRen2-27 to Fischer and Lewis female rats andaverage of the two measures was used in the analysis.
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Fig. 4. LOD score of the markers on chromo-
somes 10 (A) and 17 (B). The highest LOD
scores were found close to the Ace and At1 loci.
LOD values for the traits survival (broken line)
and age of death (AoD; solid line) are from
interval mapping analysis [17, 18]. The broken,
horizontal line is the LOD threshold for signifi-
cant linkage [19] (cM, centiMorgan).
monitored the clinical symptoms of MH, which include Blood pressure was determined at six and eight weeks
of age prior to the development of MH and showed nopolyuria, weight loss, lethargy, piloerection, hemiparesis,
seizure, and lethality in the progeny. With a single excep- significant difference in systolic blood pressure between
the survivors and the MH group (Fig. 3).tion (83 days), all male progeny from Fischer females
developed terminal MH between 50 and 70 days of age
Linkage and quantitative trait loci analyses(mean age 56.9 6 5.6 days), whereas 41.5% of Lewis
progeny survived over 120 days without symptoms (mean We screened 125 informative microsatellite markers
distributed over the entire rat genome. QTL analyses ofAoD in Lewis progeny developing MH was 62.0 6 6.2
days; Table 1). To genetically map the polymorphic ge- either “survival,” as a binomial trait, or “AoD,” as a
quantitative phenotype, identified linkage with two chro-netic loci conferring susceptibility to MH and mortality,
we crossed F1 Fischer-Lewis hybrid females to the same mosomal regions. The first locus was identified on chro-
mosome 10 at or close to the Ace gene with a LOD scoresingle homozygous TGRmRen2-27 SD male. All prog-
eny were obligate Ren2 heterozygotes and, for any given of 3.9 for “survival” and 4.4 for “AoD” (Fig. 4). This
locus reduced the life span by 7.3 6 1.6 days and in-locus, carried one SD allele and a second allele of either
Fischer or Lewis origin. Among the 252 male progeny creased the probability of MH by 4.2-fold (P , 0.0001
by univariate analysis) in animals inheriting a Fischerobtained and phenotyped, 79.4% developed MH (mean
age 63.3 6 12.2 days; Fig. 1). Those showing no symptoms allele in comparison to those inheriting a Lewis allele.
The second locus was identified on chromosome 17 inby 120 days were scored as “survivors.”
Histological examination showed the presence of fi- the region close to the gene encoding the type 1 angioten-
sin receptor, At1, at which the LOD score for “AoD” wasbrinoid necrosis, intimal proliferation, and acute neph-
ron injury in all animals (Fig. 2). Additional features in 3.9 (Fig. 4). The LOD score for “survival” was maximal in
the same chromosomal region but did not reach signifi-those who had survived beyond 120 days were nephro-
sclerosis, tubular atrophy, and fibrosis of arterial walls. cance (LOD 2.1). At this locus, the inheritance of a Lewis
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Table 2. Survival analysis with reference to the genotype ofTable 1. Incidence of lethal malignant hypertensive phenotype
(MH) in three heterozygote crosses produced by breeding a single Ace (chromosome 10) and At1 (chromosome 17) loci
male TGRmRen2-27 to females of different strains
Genotype MH Survivors
MH Survivors
Ace At1 (N) Odds ratio (95% CI)Heterozygote crosses (N) (N) % MH
LS FSa 40 28 1TGRmRen2-27 3 F1 (Fischer-Lewis) 200 52 79.4 LS LS 48 12 2.8 (1.3–6.2)TGRmRen2-27 3 Fischer 53 0 100
FS FS 57 9 4.4 (1.9–10.4)TGRmRen2-27 3 Lewis 31 22 58.5
FS LS 55 3 12.8 (3.6–45.2)
Total 200 52
FS represents the Fischer/Sprague-Dawley haplotype and LS represents the
Lewis/Sprague-Dawley haplotype.
a Reference group
allele rather than a Fischer allele reduced the life span
by 6.9 6 1.6 days and increased the probability of MH by
2.6-fold (P 5 0.006 by univariate analysis). The genome-
spontaneously hypertensive rats (SHRSPHD) and the nor-wide screening found no significant evidence for linkage
motensive Wistar-Kyoto (WKYHD-0) reference strain [22].of either “survival” or “AoD” to other chromosomes
It is possible that altered expression of the Ace gene in(all LOD scores were less than 1.5). Moreover, there
Fischer rats contributed to development of MH and mor-was no effect of both loci on the trait “blood pressure”
tality, and we observed higher plasma ACE activity inat six and eight weeks, as detected by QTL analysis.
TGRmRen2-27 3 Fischer F1 progeny than in TGRmRen2-
Epistasis of linkage loci 27 3 Lewis F1 progeny. Furthermore, the association of
the deletion polymorphism of the Ace gene and end organTo test for interaction between the Ace and At1 loci,
damage in human cardiovascular and renal disease haswhose products act downstream of renin in the RAS, we
been well documented [23–29]. ACE may regulate vasore-analyzed “survival” with reference to the genotype of the
activity and vascular response to hypertensive injury byAce and At1 loci. The risk of lethality from MH increased
altering the concentration of angiotensin II, which is2.8-, 4.4-, and 12.8-fold in animals carrying susceptibility
known to have effects on cell growth and extracellularalleles on chromosomes 17, 10, and both chromosomes,
matrix formation [30–32] and thereby affect the pro-respectively, when compared with animals without the
cesses leading to organ damage and mortality from MH.susceptibility loci (Table 2), and these data are consistent
Quantitative trait loci analysis suggested that a locuswith a multiplicative effect of the two loci.
on chromosome 17 at or near the At1 gene, which en-
Plasma angiotensin-converting enzyme activity in codes the angiotensin II receptor type I, may affect the
different F1 progeny timing of mortality from MH. The finding that down-
regulation of this receptor occurs in TGRmRen2-27 ratsTo test the hypothesis of the association of the Ace
[33] supports the hypothesis that the At1 gene may play agene and its product in the development of MH pheno-
role in the MH phenotype, possibly by genotype-specifictype, we measured plasma ACE activity in Fischer and
differences in receptor regulation. The interaction be-Lewis progeny. We found a higher plasma ACE activity
tween the effects of the loci on chromosome 10 and 17in F1 progeny of TGRmRen2-27 3 Fischer than in F1
further supports the hypothesis that both the Ace andprogeny of TGRmRen2-27 3 Lewis (123.5 6 9.5 vs.
At1 genes are likely to be candidate genes determining91.8 6 4.9 U/liter, P , 0.01, N 5 15 and 16).
the lethal MH phenotype, and indeed the interaction
between these loci has been found in human myocardial
DISCUSSION infarction [34]. From our previous studies [11, 12], we
We applied genetic analysis to map modifier loci in- found a low penetrance of MH in the “Hannover” SD
fluencing the MH phenotype caused by the interaction background, and it was clear that “Hannover” SD alleles
between the Ren2 transgene and the Fischer F344 and did not contribute to the MH phenotype in a dominant
Lewis genetic backgrounds. We found linkage of MH manner. Those data are consistent with our study in
with loci on chromosomes 10 and 17 close to the Ace which the data suggest that the Fischer locus on chromo-
and At1 genes, respectively. Both Ace and At1 can be some 10 and the Lewis locus on chromosome 17 have a
considered as candidate genes contributing to lethality dominant effect on the MH phenotype.
from MH, because the RAS is known to be involved in Quantitative trait loci analysis showed no linkage of
the pathophysiology, and subhypotensive doses of ACE loci on chromosomes 10 and 17 with blood pressure at
inhibitors prevent mortality from MH in this model [21]. six and eight weeks of age. Moreover, we found no differ-
The Ace locus has previously been shown to determine ence in blood pressure between survivors and the MH
plasma ACE activity but had no direct effect on blood group prior to the development of MH, which was consis-
tent with the previous report [12]. These data suggest thatpressure in an F2 intercross between the stroke-prone
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